Recently, studies have shown that targeting TPX2 in breast and prostate cancer lowered the rate of chromosome missegregation, and have therefore regarded TPX2 as a candidate biomarker for treatment (Pan et al., 2017). This evidence concerns the gene TPX2 and prostate cancer.